Marvel Biosciences Secures Japanese Patent for Autism Spectrum Disorder Therapeutic MB-204
Key Insights
Marvel Biosciences received Japanese patent protection for MB-204, a novel fluorinated analogue of Istradefylline targeting autism spectrum disorder (search) and related neurological conditions.
The compound has demonstrated improved pharmacokinetics and shown robust preclinical efficacy in depression (search) and multiple autism models, including Rett syndrome (search).
This marks the second major jurisdiction to grant composition-of-matter patent protection for MB-204, strengthening the company's global intellectual property portfolio.
Marvel Biosciences Corp. (search) has received Japanese patent protection for its lead therapeutic candidate MB-204, a novel compound designed to treat autism spectrum disorder (search) and related neurological conditions. The Japan Patent Office granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders," covering composition of matter and methods of use claims for the experimental drug.
"This represents the second major jurisdiction to grant a composition-of-matter patent for our lead molecule MB-204," said Rod Matheson, CEO of Marvel Biosciences. "Securing patent protection in Japan significantly strengthens our global intellectual property portfolio and further enhances the long-term value of MB-204 as we advance toward clinical development."
Novel Adenosine A2A Receptor Antagonist
MB-204 is a novel fluorinated analogue of Istradefylline, an approved adenosine A2A receptor (search) antagonist currently used in the treatment of Parkinson's disease (search). The compound has demonstrated improved pharmacokinetics relative to the parent compound and has completed preclinical toxicology testing.
The therapeutic candidate has shown robust preclinical efficacy in models of depression (search) and multiple models of autism, including Rett syndrome (search). The compound is currently being evaluated in Fragile X syndrome (search) models, expanding its potential therapeutic applications across neurodevelopmental disorders.
Addressing Unmet Medical Need
Autism spectrum disorder (search) affects approximately 1 in 36 children by age eight, underscoring the urgent need for new therapeutic options that address its core symptoms. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression (search), and Alzheimer's disease (search).
Marvel believes MB-204's differentiated pharmacological profile and expanding global patent coverage position the compound for continued development and potential strategic partnerships. The company is also exploring MB-204's potential in rare disorders like Rett syndrome (search) and Fragile X syndrome (search), aiming to bring new options to patients with few effective treatments.
Company Background
Marvel Biosciences Corp. (search), through its wholly owned subsidiary Marvel Biotechnology Inc. (search), is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. MB-204 represents a novel fluorinated derivative version of Istradefylline, which is currently the only adenosine A2A receptor (search) blocker on the market.
The patent grant in Japan follows previous intellectual property protection in another major jurisdiction, building the company's global patent portfolio as it prepares to advance MB-204 toward clinical development phases.